The Thyroid Cancer Care Collaborative developed a web-based clinical decision-making module (CDMM) to inform riskadjusted decisions on post-thyroidectomy radioactive iodine (RAI) use in papillary thyroid cancer (PTC). Methods: In a pilot study, we evaluated the CDMM in 19 PTC cases representing low-(five), intermediate-(seven) and high-risk (seven) disease. Two PTC experts and 10 PTC physicians reviewed cases and assigned risk level and RAI recommendation. The experts used a standard approach while the others used the CDMM. We assessed agreement between responses using a weighted Kappa. Results: Between experts, risk-assignment was concordant in 100%, 57% and 86% of low-, intermediate-and high-risk cases, respectively. Between CDMM users, risk-assignment was concordant in 100%, 29% and 14% in low-, intermediate-and high-risk cases, respectively (p=0.01). CDMM-assigned risk agreed with the expert-assigned risk in 100%, 25% and 0% of low-, intermediate-and high-risk cases, respectively (Kappa=0.69). For RAI use, the experts agreed in 15 cases while CDMM users agreed in eight. On further analysis, interpretation of extrathyroidal extension and lymph node staging led to discrepancies with the CDMM. Conclusions: For a web-based CDMM to accurately inform appropriate use of RAI in PTC, standard pathological and surgical reports are necessary.
The incidence of thyroid cancer is increasing at a rate of 7% a year; there were an estimated 62,450 cases diagnosed in the US in 2015 alone. The majority of this rise in incidence is explained by the growing number of incidentally detected well-differentiated, early-stage or 'low-risk' papillary thyroid cancers (PTCs). 3 There is a growing awareness that many thyroid cancers may indeed be relatively benign in their behaviour and can be followed without any intervention. 4 As a result, the management of differentiated thyroid cancer has undergone a major paradigm shift over the last two decades from a 'one size fits all' to a 'risk-adapted' approach. The American Thyroid Association (ATA) has led this effort by developing and publishing evidence-based guidelines on thyroid cancer management. The ATA guidelines incorporate tumour and patient characteristics to estimate the initial risk of recurrence (prognostication) and then use this information to inform recommendations on the use of adjuvant radioactive iodine (RAI) or remnant ablation therapy and the intensity and method of surveillance. 5 One major goal of the ATA guidelines is to minimise potential harm from overtreatment for low-risk patients, while appropriately treating high-risk patients.
In well-differentiated thyroid cancer, adjuvant RAI is an effective method of attempting to address microscopic disease both in the thyroid bed (remnant thyroid) and distant metastatic sites.
The phrases remnant ablation and adjuvant therapy are often used interchangeably, but there are distinct differences. A lower dose of RAI, 30 to 50 mCi (or 1,110 to 1,850 MBq) is used for remnant ablation while a higher dose, 100 to 150 mCi (3,700 to 5,550 MBq) is reserved for adjuvant therapy in patients deemed at high risk of micrometastatic disease. 6 The use of RAI improves survival and decreases recurrence rates for high-risk patients with extensive disease, but does not change the already excellent prognosis of patients with low-risk disease. [7] [8] [9] The use of post-thyroidectomy RAI has dramatically risen over the last three decades as part of the first course of therapy for thyroid cancer from 6.1% of cases treated in 1973 to 48.7% of cases treated in 2006. 10 During the same time frame, an increasing proportion of patients have been diagnosed with low-risk thyroid cancer raising the question of benefit of added RAI therapy. 3 Early recommendations on RAI use were shaped by retrospective studies completed in the 1970-80's that reported decreased risk of recurrence in patients who received RAI therapy compared with those treated with surgery and thyroid suppression alone. risk subgroup of patients. 13 To improve dissemination of the new 2015 guidelines into clinical practice, the Thyroid Cancer Care Collaborative 
Methods
The TCCC is an online Health Insurance Portability and Accountability For each selected case, a de-identified file containing the relevant clinical information that would have been available at time of a decision regarding adjuvant RAI was created. These files were provided to two experts (RMT, LW) who were asked to render a 'yes' or 'no' decision on the use of RAI for each case. The gold standard was deemed to be an agreement decision between two experts. Ten thyroid cancer fellows from endocrinology and surgery in fellowship at a specialised cancer centre were invited to participate (five endocrinology; five head and neck surgical fellows) and asked to use the CDMM to render a response of 'yes', 'no' or 'consider' regarding adjuvant RAI for the same 19 cases.
The number and percent of cases where all fellows agreed was described overall and by risk of recurrence based on ATA guidelines.
The distribution of fellow's responses was described for various types of cases. In cases of disagreement between the fellows, the question(s) on the CDMM causing disagreement was/were identified. Agreement between the fellows was assessed using weighted Kappa with equal weights, i.e. the distance from 'no' to 'consider' is equal to the distance from 'consider' to 'yes'. (All statistical analysis was performed at R 3.1.1.R Foundation, Vienna, Austria) and the irr package was used.
Results

Case descriptions
The 19 cases randomly selected for this study represented a range of PTCs. There were five low-risk cases (26%), seven intermediate-risk cases (37%) and seven high-risk cases (37%). Of these cases, 10 patients were male (53%); seven patients were under 45 years of age (37%) at diagnosis.
Provider decisions regarding use of adjuvant radioactive iodine therapy
The experts had complete agreement in 15 out of 19 cases (79%) (see Table 1 ). There were 10 cases that were 'yes' agreement; five cases that were 'no' agreement. The experts agreed on 100%, 57% and 86% of low- 
Level of agreement by risk category
In the 15 cases where a gold standard was established (agreement between the two experts), the fellows all agreed in 100% of the low- The experts agreed in four intermediate-risk cases 'yes' give RAI, and the fellows agreed 'consider' in one of these cases. The experts agreed in six high-risk cases 'yes' give RAI, and the fellows did not agree on any of these cases (see Figure 3) .
The experts agreed to give RAI in nine cases that the fellows disagreed on: Three intermediate-risk cases; six high-risk cases. Of the three intermediate-risk cases, the experts agreed 'yes' for, the fellows split between 'consider' and 'no' in two cases and 'yes' and 'consider' in one. Of the high-risk cases the experts agreed 'yes' for, the fellows split between 'yes' and consider' in six cases, and between all three possible answers (yes', 'no' and 'consider') in one.
There were four cases of 'yes'/'no' disagreement between experts, three were intermediate-risk cases, and one was a high-risk case. In one of the intermediate-risk cases and the high-risk case, the 10 fellows agreed 'consider'. In the other two cases the experts disagreed on, the fellows also disagreed, in one case splitting between 'yes' and 'consider', and in the other between 'no' and 'consider'.
Pathology reports
In a secondary analysis, when evaluating responses to feeder items in the CDMM, two main issues arose. First, there was disagreement about the presence of gross extrathyroidal extension. The CDMM, will always instruct 'yes' to give RAI if there is gross extrathyroidal extension. In all cases where there was 'yes'/'consider' disagreement, the difference was attributable to the answer to gross extrathyroidal extension. The second cause of disagreement was response to N1a disease. In the absence of N1a disease, the CDMM will instruct 'no' to RAI. In the cases where there was 'no'/'consider' disagreement, the only response that differed among fellows was the item on N1a disease.
Discussion
This pilot study confirmed that a web-based decision aid, the CDMM for 14 Another area that presented clinical uncertainty was the distinction of N1a lymph nodes, which can be confusing if not explicitly stated by a surgeon or pathologist given the need to understand neck anatomy.
Although we did not explicitly ask the experts and fellows to stage the disease, we suspect that there was some confusion interpretation between N1a and N1b disease.
It would appear that based on the 19 cases selected for this pilot study, the CDMM for post-treatment RAI may work best for cases that physicians Feedback from this study has been taken back to the TCCC and a morerefined version of the CDMM on RAI therapy will be tested again using cases from after 2005 when our institutional pathology and operative reports for thyroid cancer were standardised to avoid confusion or misinterpretation of these key clinical features.
Conclusions
The TCCC has developed a web-based clinical decision aid that is 
